Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
10
2020
accepted:
31
01
2021
entrez:
16
2
2021
pubmed:
17
2
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Libman-Sacks endocarditis in patients with systemic lupus erythematosus (SLE) is commonly complicated with embolic cerebrovascular disease (CVD) or valve dysfunction for which high-risk valve surgery is frequently performed. However, the role of medical therapy alone for Libman-Sacks endocarditis and associated acute CVD remains undefined. To determine in this cross-sectional and longitudinal study if conventional anti-inflammatory and anti-thrombotic therapy may be an effective therapy in SLE patients with Libman-Sacks endocarditis and associated acute CVD. 17 SLE patients with Libman-Sacks endocarditis detected by two-and-three-dimensional transesophageal echocardiography (TEE) and complicated with acute CVD [stroke/TIA, focal brain injury on MRI, or cognitive dysfunction] were treated with conventional anti-inflammatory and anti-thrombotic therapy for a median of 6 months and then underwent repeat TEE, transcranial Doppler, brain MRI, and neurocognitive testing for re-assessment of Libman-Sacks endocarditis and CVD. Valve vegetations decreased in number, diameter, and area (all p ≤0.01); associated valve regurgitation significantly improved (p = 0.04), and valve thickening did not progress (p = 0.56). In 13 (76%) patients, valve vegetations or valve regurgitation resolved or improved in number and size or by ≥1 degree, respectively, as compared to 4 (24%) patients in whom vegetations or valve regurgitation persisted unchanged or increased in size or by ≥1 degree (p = 0.03). Also, cerebromicroembolism, lobar and global gray and white matter cerebral perfusion, ischemic brain lesion load, and neurocognitive dysfunction resolved or significantly improved (all p ≤0.04). These preliminary data suggest that combined conventional anti-inflammatory and antithrombotic therapy may be an effective treatment for Libman-Sacks endocarditis and its associated CVD and may obviate the need for high-risk valve surgery.
Sections du résumé
BACKGROUND
Libman-Sacks endocarditis in patients with systemic lupus erythematosus (SLE) is commonly complicated with embolic cerebrovascular disease (CVD) or valve dysfunction for which high-risk valve surgery is frequently performed. However, the role of medical therapy alone for Libman-Sacks endocarditis and associated acute CVD remains undefined.
OBJECTIVE
To determine in this cross-sectional and longitudinal study if conventional anti-inflammatory and anti-thrombotic therapy may be an effective therapy in SLE patients with Libman-Sacks endocarditis and associated acute CVD.
METHODS AND MATERIALS
17 SLE patients with Libman-Sacks endocarditis detected by two-and-three-dimensional transesophageal echocardiography (TEE) and complicated with acute CVD [stroke/TIA, focal brain injury on MRI, or cognitive dysfunction] were treated with conventional anti-inflammatory and anti-thrombotic therapy for a median of 6 months and then underwent repeat TEE, transcranial Doppler, brain MRI, and neurocognitive testing for re-assessment of Libman-Sacks endocarditis and CVD.
RESULTS
Valve vegetations decreased in number, diameter, and area (all p ≤0.01); associated valve regurgitation significantly improved (p = 0.04), and valve thickening did not progress (p = 0.56). In 13 (76%) patients, valve vegetations or valve regurgitation resolved or improved in number and size or by ≥1 degree, respectively, as compared to 4 (24%) patients in whom vegetations or valve regurgitation persisted unchanged or increased in size or by ≥1 degree (p = 0.03). Also, cerebromicroembolism, lobar and global gray and white matter cerebral perfusion, ischemic brain lesion load, and neurocognitive dysfunction resolved or significantly improved (all p ≤0.04).
CONCLUSION
These preliminary data suggest that combined conventional anti-inflammatory and antithrombotic therapy may be an effective treatment for Libman-Sacks endocarditis and its associated CVD and may obviate the need for high-risk valve surgery.
Identifiants
pubmed: 33592060
doi: 10.1371/journal.pone.0247052
pii: PONE-D-20-32593
pmc: PMC7886205
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247052Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Cardiothorac Surg. 2010 Mar 23;5:13
pubmed: 20331896
Nat Rev Rheumatol. 2012 Sep;8(9):522-33
pubmed: 22801982
Am J Cardiol. 2005 Jun 15;95(12):1441-7
pubmed: 15950567
N Engl J Med. 2003 Sep 18;349(12):1133-8
pubmed: 13679527
Circ J. 2018 Aug 24;82(9):2380-2382
pubmed: 29467357
J Am Coll Cardiol. 1992 Nov 1;20(5):1127-34
pubmed: 1341885
Circulation. 1996 Apr 15;93(8):1579-87
pubmed: 8608627
Ann Rheum Dis. 2012 Nov;71(11):1771-82
pubmed: 22851469
Eur Heart J Case Rep. 2019 Sep 1;3(3):
pubmed: 31377769
Reumatol Clin. 2018 Sep - Oct;14(5):269-277
pubmed: 28291723
Arthritis Rheum. 2007 Dec 15;57(8):1487-95
pubmed: 18050167
J Thromb Haemost. 2005 May;3(5):848-53
pubmed: 15869575
N Engl J Med. 1995 Apr 13;332(15):993-7
pubmed: 7885428
JACC Cardiovasc Imaging. 2013 Sep;6(9):973-83
pubmed: 24029368
Ann Rheum Dis. 1977 Dec;36(6):508-16
pubmed: 339850
Case Rep Cardiol. 2016;2016:3250845
pubmed: 27610249
Semin Arthritis Rheum. 1999 Dec;29(3):182-90
pubmed: 10622682
Eur J Cardiothorac Surg. 2010 Jan;37(1):154-8
pubmed: 19699100
Turk Kardiyol Dern Ars. 2019 Dec;47(8):687-690
pubmed: 31802766
Ann Rheum Dis. 2019 Jun;78(6):736-745
pubmed: 30926722
Rheumatology (Oxford). 2019 Jun 1;58(6):969-974
pubmed: 30508199
J Am Soc Echocardiogr. 2015 Jul;28(7):770-9
pubmed: 25807885
J Rheumatol. 2010 Sep;37(9):1834-43
pubmed: 20551095
ScientificWorldJournal. 2014;2014:216291
pubmed: 25401131
Gen Thorac Cardiovasc Surg. 2012 Dec;60(12):822-6
pubmed: 22588542
N Engl J Med. 1996 Nov 7;335(19):1424-30
pubmed: 8875919
Blood. 2010 Mar 18;115(11):2292-9
pubmed: 19965621
Thromb Haemost. 2006 Jun;95(6):949-57
pubmed: 16732373
Ann Rheum Dis. 2019 Oct;78(10):1296-1304
pubmed: 31092409
Lupus. 1996 Jun;5(3):196-205
pubmed: 8803890
Thromb Haemost. 2002 Mar;87(3):518-22
pubmed: 11916085
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Rheumatology (Oxford). 2015 Jul;54(7):1270-8
pubmed: 25638807
J Am Soc Echocardiogr. 1996 Jan-Feb;9(1):104-7
pubmed: 8679231
Lupus. 2017 Oct;26(11):1149-1156
pubmed: 28420053
Arthritis Rheum. 2004 Oct 15;51(5):810-8
pubmed: 15478145
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S37-46
pubmed: 22588757
Front Hum Neurosci. 2010 Apr 19;4:27
pubmed: 20428508
Lupus. 2006;15(9):577-83
pubmed: 17080912
J Neuroimaging. 2010 Oct;20(4):359-67
pubmed: 19912481